{"id":535,"date":"2020-09-15T10:01:00","date_gmt":"2020-09-15T10:01:00","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=535"},"modified":"2020-09-15T10:01:00","modified_gmt":"2020-09-15T10:01:00","slug":"12-sep-2020-tocilizumab-early-dosing-associated-with-increased-survival","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/12-sep-2020-tocilizumab-early-dosing-associated-with-increased-survival\/","title":{"rendered":"(12 Sep 2020) Tocilizumab- early dosing associated with increased survival"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2<\/p>\n<p>https:\/\/doi.org\/10.1111\/cts.12894<\/p>\n<p class=\"\">This was a multi-center study with data collected by chart review both retrospectively and concurrently. &nbsp;145 patients were evaluated. The average age was 58.1 years, 64% were male, 68.3% had comorbidities, and 60% received steroid therapy. Disposition of patients was 48.3% discharged and 29.3% expired, of which 43.9% were African American. Mechanical ventilation was required in 55.9%, of which 34.5% expired. Avoidance of MV (p value = 0.002) and increased survival (p value &lt; 0.001) was statistically associated with early dosing. Tocilizumab therapy was effective at decreasing mortality and should be instituted early in the management of critically ill COVID-19 patients.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2 https:\/\/doi.org\/10.1111\/cts.12894 This was a multi-center study with data collected by chart review both retrospectively and concurrently. &nbsp;145 patients were evaluated. The average age was 58.1 years, 64% were&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/12-sep-2020-tocilizumab-early-dosing-associated-with-increased-survival\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(12 Sep 2020) Tocilizumab- early dosing associated with increased survival&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/535"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=535"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/535\/revisions"}],"predecessor-version":[{"id":536,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/535\/revisions\/536"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}